Sponsor:
35Pharma Inc
Code:
NCT07123779
Conditions
Pulmonary Hypertension
Heart Failure With Preserved Ejection Fraction
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
HS235
Placebo
Brief summary:
Conditions
Pulmonary Hypertension
Heart Failure With Preserved Ejection Fraction
Study ID
NCT07123779
Start date
Aug, 2026
Status verified date
Aug, 2026
Completion date
Jan, 2030
Anticipated
Primary completion date
Jan, 2029
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
126 participants
Anticipated
Allocation
Randomized
Intervention Model
Sequential
Primary purpose
Treatment
Arms
experimental: Investigational Product
placebo comparator: Placebo
Interventions
HS235
Placebo
Primary outcome measure
Central contacts
Locations
Investigational Site-101
Recruiting
Greenville, South Carolina, United States, 29605
Sponsor
35Pharma Inc
Last update posted
Aug 17, 2026
Last verified
Aug, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by 35Pharma Inc on 2026-08-17.